Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
20 Jan 2022

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )
19 Jan 2022

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more ( Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer )
19 Jan 2022

OncoAlert Colloquium Day 4: GI oncology and EONS

Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken
OncoAlert Colloquium Day 4: GI oncology and EONS ( Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken )
19 Jan 2022

OncoAlert Colloquium Day 3: Breast cancer

Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara Tolaney, Dr Matteo Lambertini & Dr Icro Meattini
OncoAlert Colloquium Day 3: Breast cancer ( Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara Tolaney, Dr Matteo Lambertini & Dr Icro Meattini )
19 Jan 2022

OncoAlert Colloquium Day 2: Lung cancer and MASCC

Dr Stephen Liu, Dr Jack West, Dr Sanay Popat, Dr Jarushka Naidoo, Dr Percy Lee, Ms Jill Feldman, Ms Ivy Elkins, Dr Andrew Davies & Dr Joanne Bowen
OncoAlert Colloquium Day 2: Lung cancer and MASCC ( Dr Stephen Liu, Dr Jack West, Dr Sanay Popat, Dr Jarushka Naidoo, Dr Percy Lee, Ms Jill Feldman, Ms Ivy Elkins, Dr Andrew Davies & Dr Joanne Bowen )
19 Jan 2022

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology

Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology ( Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti )
19 Jan 2022

Social distancing and economic crisis in Latin America during the COVID-19 pandemic

Prof Richard Sullivan and Prof Bettina Müller
Social distancing and economic crisis in Latin America during the COVID-19 pandemic ( Prof Richard Sullivan and Prof Bettina Müller )
10 Jan 2022

Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma

Prof Pamela Allen - Emory University School of Medicine, Georgia, USA
Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )
22 Dec 2021

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
22 Dec 2021

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

Dr Sara Hurvitz - University of California, Los Angeles, USA
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ( Dr Sara Hurvitz - University of California, Los Angeles, USA )
21 Dec 2021

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease

Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease ( Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA )
21 Dec 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation